ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 43, 2016, Pages E6669-E6678

  Gregory, Mark A ^a,b   D'Alessandro, Angelo ^a,b   Alvarez Calderon, Francesca ^a,b   Kim, Jihye ^b   Nemkov, Travis ^a,b   Adane, Biniam ^b   Rozhok, Andrii I ^a,b   Kumar, Amit ^a   Kumar, Vijay ^a   Pollyea, Daniel A ^b   Wempe, Michael F ^a   Jordan, Craig T ^b   Serkova, Natalie J ^b   Tan, Aik Choon ^a,b   Hansen, Kirk C ^a,b   DeGregori, James ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Acute myeloid leukemia; ATM; FLT3; Glutathione; Metabolism

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; CARBON; CD135 ANTIGEN; ELESCLOMOL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HISTONE H2AX; LESTAURTINIB; PHENFORMIN; PRASTERONE; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TIGECYCLINE; ANTINEOPLASTIC AGENT; ATM PROTEIN, HUMAN; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; FLT3 PROTEIN, HUMAN; HYDRAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARBON METABOLISM; CELL KILLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; METABOLOME; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RNA INTERFERENCE; ACUTE MYELOID LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BENZOTHIAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; HYDRAZINES; LEUKEMIA, MYELOID, ACUTE; MICE, INBRED NOD; MIDDLE AGED; OXIDATION-REDUCTION; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84992315972     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1603876113     Document Type: Article

References (54)

1. Stone RM, O'Donnell MR, Sekeres MA (2004) Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004:98-117.
2. Dinner SN, Giles FJ, Altman JK (2014) New strategies for relapsed acute myeloid leukemia: Fertile ground for translational research. Curr Opin Hematol 21(2):79-86.
3. Paterson SC, Smith KD, Holyoake TL, Jørgensen HG (2003) Is there a cloud in the silver lining for imatinib? Br J Cancer 88(7):983-987.
4. Scholl C, Gilliland DG, Fröhling S (2008) Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 35(4):336-345.
5. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059-2074.
6. Swords R, Freeman C, Giles F (2012) Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 26(10):2176-2185.
7. Armstrong SA, et al. (2004) FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103(9):3544-3546.
8. Small D (2006) FLT3 mutations: Biology and treatment. Hematology Am Soc Hematol Educ Program 2006:178-184.
9. Levis M, Small D (2003) FLT3: ITDoes matter in leukemia. Leukemia 17(9):1738-1752.
10. Smith CC, et al. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397):260-263.
11. Pratz KW, Luger SM (2014) Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? Curr Opin Hematol 21(2):72-78.
12. Kim J, Tan AC (2012) BiNGS!SL-seq: A bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. Methods Mol Biol 802:389-398.
13. Ambrose M, Gatti RA (2013) Pathogenesis of ataxia-telangiectasia: The next generation of ATM functions. Blood 121(20):4036-4045.
14. Levis M (2014) Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncol 10(9):1571-1579.
15. Cosentino C, Grieco D, Costanzo V (2011) ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 30(3):546-555.
16. Pallardó FV, et al. (2010) Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Biogerontology 11(4):401-419.
17. Valentin-Vega YA, et al. (2012) Mitochondrial dysfunction in ataxia-telangiectasia. Blood 119(6):1490-1500.
18. Morita A, Tanimoto K, Murakami T, Morinaga T, Hosoi Y (2014) Mitochondria are required for ATM activation by extranuclear oxidative stress in cultured human hepatoblastoma cell line Hep G2 cells. Biochem Biophys Res Commun 443(4):1286-1290.
19. Dickinson BC, Chang CJ (2008) A targetable fluorescent probe for imaging hydrogen peroxide in the mitochondria of living cells. J Am Chem Soc 130(30):9638-9639.
20. Alvarez-Calderon F, et al. (2015) Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res 21(6):1360-1372.
21. Jacquel A, et al. (2003) Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17(14):2160-2162.
22. Blackman RK, et al. (2012) Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One 7(1):e29798.
23. Miskimins WK, et al. (2014) Synergistic anti-cancer effect of phenformin and oxamate. PLoS One 9(1):e85576.
24. Skrtić M, et al. (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20(5):674-688.
25. Yoon JY, Ishdorj G, Graham BA, Johnston JB, Gibson SB (2014) Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells. Apoptosis 19(1):191-200.
26. Kirshner JR, et al. (2008) Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7(8):2319-2327.
27. Nagai M, et al. (2012) The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic BiolMed 52(10):2142-2150.
28. Hasinoff BB, Yadav AA, Patel D, Wu X (2014) The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu (II). J Inorg Biochem 137:22-30.
29. Pagliarini R, Shao W, Sellers WR (2015) Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep 16(3):280-296.
30. Torti D, Trusolino L (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: Promises and perils. EMBO Mol Med 3(11):623-636.
31. Glasauer A, Chandel NS (2014) Targeting antioxidants for cancer therapy. Biochem Pharmacol 92(1):90-101.
32. Weinberg F, et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107(19):8788-8793.
33. Maryanovich M, Gross A (2013) A ROS rheostat for cell fate regulation. Trends Cell Biol 23(3):129-134.
34. DeNicola GM, et al. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106-109.
35. Wondrak GT (2009) Redox-directed cancer therapeutics: Molecular mechanisms and opportunities. Antioxid Redox Signal 11(12):3013-3069.
36. Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12):931-947.
37. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8(7):579-591.
38. Ribas V, García-Ruiz C, Fernández-Checa JC (2014) Glutathione and mitochondria. Front Pharmacol 5:151.
39. Pei S, et al. (2013) Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem 288(47):33542-33558.
40. Canman CE, Lim DS (1998) The role of ATM in DNA damage responses and cancer. Oncogene 17(25):3301-3308.
41. Shiloh Y, Ziv Y (2013) The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197-210.
42. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT (2010) ATM activation by oxidative stress. Science 330(6003):517-521.
43. Li Y, Yang DQ (2010) The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther 9(1):113-125.
44. Alexander A, et al. (2010) ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 107(9):4153-4158.
45. Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3(9):650-665.
46. Wise DR, Thompson CB (2010) Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 35(8):427-433.
47. Daye D, Wellen KE (2012) Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23(4):362-369.
48. Auclair D, et al. (2007) Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21(3):439-445.
49. Gregory MA, et al. (2010) Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 18(1):74-87.
50. D'Alessandro A, et al. (2014) Metabolic effect of TAp63α: Enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense. Oncotarget 5(17):7722-7733.
51. Porter CC, et al. (2012) Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 12(12):2675-2684.
52. Mi H, Muruganujan A, Casagrande JT, Thomas PD (2013) Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8(8):1551-1566.
53. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ (2004) Imatinib (STI571) - mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 10(19):6661-6668.
54. Klawitter J, et al. (2009) Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 158(2):588-600.